for 7 of 41 batches marketed in Poland, out‑of‑specification results for atomoxetine content were found in reference samples, below the lower specification limit; the medical risk assessment indicated possible low effectiveness of the medicine. Potential effects: reduced therapeutic efficacy, risk of lack of the expected treatment effect.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use the medicine from the listed batches; check the batch number on the packaging and, if you possess the product, return it to a pharmacy or consult a doctor or pharmacist for further advice.
The specified batches of the medicinal product Konaten (Atomoxetine) were withdrawn from the market throughout the country, marketing of these batches was prohibited, and the decision was given immedi...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related